Fibrocell Science, Inc.
FCSC evidence brief
What we can confirm
- BioSniper Score:
- 5.3 / 10
- Lead Asset:
- fcx-007 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for FCSC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
fcx-007 (Phase 1/Phase 2)
Next Catalyst
—
Tracking 2 pipeline candidates for Fibrocell Science, Inc..
Run Fibrocell Science, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Fibrocell Science, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1/Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Fibrocell Science, Inc.'s lead drug candidate?
Fibrocell Science, Inc.'s most advanced tracked candidate is fcx-007 (Phase 1/Phase 2) for recessive dystrophic epidermolysis bullosa (RDEB).
Who is the CEO of Fibrocell Science, Inc.?
Important Notice Regarding is the chief executive officer of Fibrocell Science, Inc. (FCSC).
What therapeutic areas does Fibrocell Science, Inc. focus on?
Fibrocell Science, Inc. develops therapies across Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.